Ironwood Pharmaceuticals | IRWD - Ebitda


Ironwood Pharmaceuticals reported $81.81M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Almirall EUR 114.07M 60.37M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
Ardelyx USD 6.02M 447K Dec/2025
Astellas Pharma JPY 98.93B 84.75B Mar/2026
AstraZeneca USD 5.67B 1.29B Mar/2026
Charles River Laboratories USD 229.8M 28.26M Mar/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Incyte USD 367.97M 46.53M Mar/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Moderna USD -790M 582M Dec/2025
Myriad Genetics USD 14.3M 4M Dec/2025
Pacira USD 40.24M 1.53M Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Takeda JPY 150.25B 297.88B Mar/2026
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024